https://www.nasdaq.com/press-release/anpac-bio-class-iii-medical-device-passes-extensive-nmpa-registration-tests-and-will
https://www.nasdaq.com/press-release/technical-paper-on-anpac-bio-novel-cda-cancer-detection-technology-published-by-peer
https://www.nasdaq.com/press-release/anpac-bio-reports-nine-months-ended-september-30-2021-same-period-achieved-record
https://www.nasdaq.com/press-release/correction-anpac-bio-usa-2021-11-11
https://www.nasdaq.com/press-release/anpac-bio-announces-pricing-of-approximately-%242.9-million-underwritten-public
https://www.nasdaq.com/press-release/anpac-bio-commences-proposed-public-offering-of-american-depositary-shares-2021-11-09
https://www.nasdaq.com/press-release/anpac-bio-invites-you-to-join-us-at-the-q4-virtual-investor-summit-2021-11-08
https://www.nasdaq.com/press-release/anpac-bio-study-shows-strong-correlation-between-cda-score-and-risk-of-cancer-and
https://www.nasdaq.com/press-release/anpac-bio-2021-first-half-revenue-up-128.5-with-non-gaap-loss-reduced-by-18.3-2021-10
https://www.nasdaq.com/press-release/anpac-bio-receives-nasdaq-notification-regarding-minimum-market-value-of-listed
https://www.nasdaq.com/press-release/anpac-bio-increases-ownership-percentage-of-its-subsidiary-anpai-healthcare-from-20
https://www.nasdaq.com/press-release/anpac-bios-usa-laboratory-receives-accreditation-from-the-college-of-american
https://www.nasdaq.com/press-release/anpac-bio-successfully-completes-major-preclinical-study-files-with-national-medical
https://www.nasdaq.com/press-release/anpac-bio-taps-life-sciences-and-diagnostics-veteran-as-us-ceo-2021-08-17
https://www.nasdaq.com/press-release/anpac-bio-and-roche-pharmaceuticals-china-entered-into-cooperation-to-explore
https://www.nasdaq.com/press-release/anpac-bio-announces-appointment-of-new-independent-director-2021-07-23
https://www.nasdaq.com/press-release/anpac-bio-began-generating-contract-medical-device-rd-revenue-2021-07-21
https://www.nasdaq.com/press-release/anpac-bio-pre-announces-that-during-first-half-2021-total-commercial-testing-volume
https://www.nasdaq.com/press-release/anpac-bios-first-disease-treatment-patent-granted-and-its-cancer-treatment-project
https://www.nasdaq.com/press-release/anpac-bio-reports-strong-first-quarter-in-2021-with-137.2-increase-in-revenue-and
https://www.nasdaq.com/press-release/anpac-bio-launches-novel-cancer-treatment-technology-and-product-joint-venture
https://www.nasdaq.com/press-release/anpac-bio-announces-filing-of-annual-report-on-form-20-f-for-2020-2021-04-30
https://www.nasdaq.com/press-release/anpac-bio-reports-fiscal-year-2020-annual-financial-results-89.1-increase-in-revenue
https://www.nasdaq.com/press-release/anpac-bio-to-report-fiscal-year-2020-financial-results-on-friday-april-30-2021-2021
https://www.nasdaq.com/press-release/anpac-bio-reports-record-q1-for-paid-cda-based-cancer-testing-volume-in-2021
https://www.nasdaq.com/press-release/anpac-bio-developed-and-completed-evaluations-of-new-generation-cancer-detection
https://www.nasdaq.com/press-release/anpac-bio-regains-compliance-with-nasdaq-continued-listing-requirement-2021-03-05
https://www.nasdaq.com/press-release/chinas-nmpa-approved-starting-of-registration-testing-of-anpac-bio-class-iii-medical
https://www.nasdaq.com/press-release/anpac-bio-granted-a-new-us-patent-on-novel-medical-device-for-multi-cancer-detection
https://www.nasdaq.com/press-release/anpac-bio-makes-significant-progress-in-detecting-pre-cancer-diseases-and-recorded
https://www.nasdaq.com/press-release/anpac-bio-announces-change-of-auditor-2020-12-04
https://www.nasdaq.com/press-release/anpac-bio-sets-record-test-volume-in-q3-and-forecasts-100-revenue-growth-in-2020-2020
https://www.nasdaq.com/press-release/anpac-bio-announces-appointment-of-new-independent-director-2020-11-16
https://www.nasdaq.com/press-release/anpac-bio-us-completes-covid-19-antibody-test-verification-and-approved-to-begin
https://www.nasdaq.com/press-release/anpac-bios-investee-company-in-china-received-covid-19-nucleic-acid-test
https://www.nasdaq.com/press-release/anpac-bio-completes-over-200000-biophysics-based-cancer-detection-tests-with-data
https://www.nasdaq.com/press-release/anpac-bio-to-receive-up-to-usd-%248-million-dollar-grants-and-award-for-rd-product
https://www.nasdaq.com/press-release/anpac-bio-announces-equity-investment-from-keystone-capital-partners-for-up-to-%247
https://www.nasdaq.com/press-release/tiger-asia-intelligence-reiterates-a-buy-rating-on-anpac-bio-ltd-nasdaq%3aanpc-2020-09
https://www.nasdaq.com/press-release/anpac-bio-receives-major-immunology-testing-contract-2020-09-15
https://www.nasdaq.com/press-release/anpac-bio-reports-first-six-months-of-2020-financial-results-2020-09-10
https://www.nasdaq.com/press-release/anpac-bio-announces-positive-results-from-a-multi-year-lung-cancer-prognosis-and
https://www.nasdaq.com/press-release/anpac-bio-to-report-its-first-six-months-2020-financial-results-on-thursday-september
https://www.nasdaq.com/press-release/anpac-bio-philadelphia-lab-gains-u.s.-clia-lab-certification-2020-08-24
https://www.nasdaq.com/press-release/anpac-bio-opens-us-philadelphia-lab-operations-2020-08-11
https://www.nasdaq.com/press-release/anpac-bio-validating-approved-covid-19-antibody-test-2020-08-07
https://www.nasdaq.com/press-release/anpac-bio-announces-preliminary-results-from-prospective-trials-indicating-early
https://www.nasdaq.com/press-release/anpac-bio-completes-over-180000-cda-based-cancer-risk-assessment-tests-2020-07-29
https://www.nasdaq.com/press-release/anpac-bio-completed-1st-half-year-with-increased-asp-and-revenue-2020-07-13
https://www.nasdaq.com/press-release/anpac-bio-granted-important-novel-micro-medical-device-patent-in-the-united-states
https://www.nasdaq.com/press-release/anpac-bio-medical-science-announces-cooperation-with-dragon-gate-investment-partners
https://www.nasdaq.com/press-release/anpac-bio-files-coronavirus-detection-patent-and-initiates-related-research-project
